Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:16789729rdf:typepubmed:Citationlld:pubmed
pubmed-article:16789729lifeskim:mentionsumls-concept:C1825952lld:lifeskim
pubmed-article:16789729lifeskim:mentionsumls-concept:C0231491lld:lifeskim
pubmed-article:16789729lifeskim:mentionsumls-concept:C1515655lld:lifeskim
pubmed-article:16789729lifeskim:mentionsumls-concept:C0871161lld:lifeskim
pubmed-article:16789729pubmed:issue13lld:pubmed
pubmed-article:16789729pubmed:dateCreated2006-6-22lld:pubmed
pubmed-article:16789729pubmed:abstractTextMelanin-concentrating hormone receptor antagonists containing thieno- and a benzopyridazinone cores were designed and tested as potential anorectic agents. These ligands showed high affinity for the receptor, potent functional activity in vitro, and good oral bioavailabilty in rats. The thiophene analogue exhibited low iv clearance, long half-life, and high brain penetration. In obese rats, the thienopyridazinone demonstrated a dose-dependent reduction in feeding and body weight with doses between 1 and 10 mg kg-1.lld:pubmed
pubmed-article:16789729pubmed:languageenglld:pubmed
pubmed-article:16789729pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16789729pubmed:citationSubsetIMlld:pubmed
pubmed-article:16789729pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16789729pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16789729pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16789729pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16789729pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16789729pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16789729pubmed:statusMEDLINElld:pubmed
pubmed-article:16789729pubmed:monthJunlld:pubmed
pubmed-article:16789729pubmed:issn0022-2623lld:pubmed
pubmed-article:16789729pubmed:authorpubmed-author:SaundersJohnJlld:pubmed
pubmed-article:16789729pubmed:authorpubmed-author:ConlonPaulPlld:pubmed
pubmed-article:16789729pubmed:authorpubmed-author:HeiseChristop...lld:pubmed
pubmed-article:16789729pubmed:authorpubmed-author:MadanAjayAlld:pubmed
pubmed-article:16789729pubmed:authorpubmed-author:GoodfellowVal...lld:pubmed
pubmed-article:16789729pubmed:authorpubmed-author:MarkisonStacy...lld:pubmed
pubmed-article:16789729pubmed:authorpubmed-author:SchwarzDavidDlld:pubmed
pubmed-article:16789729pubmed:authorpubmed-author:DyckBrianBlld:pubmed
pubmed-article:16789729pubmed:authorpubmed-author:GreyJonathanJlld:pubmed
pubmed-article:16789729pubmed:authorpubmed-author:RowbottomMart...lld:pubmed
pubmed-article:16789729pubmed:authorpubmed-author:WenJennyJlld:pubmed
pubmed-article:16789729pubmed:authorpubmed-author:TamiyaJunkoJlld:pubmed
pubmed-article:16789729pubmed:authorpubmed-author:ZhangMingzhuMlld:pubmed
pubmed-article:16789729pubmed:authorpubmed-author:ZhaoLirenLlld:pubmed
pubmed-article:16789729pubmed:authorpubmed-author:NortonChristi...lld:pubmed
pubmed-article:16789729pubmed:authorpubmed-author:VickersTroyTlld:pubmed
pubmed-article:16789729pubmed:authorpubmed-author:SorensenKatie...lld:pubmed
pubmed-article:16789729pubmed:issnTypePrintlld:pubmed
pubmed-article:16789729pubmed:day29lld:pubmed
pubmed-article:16789729pubmed:volume49lld:pubmed
pubmed-article:16789729pubmed:ownerNLMlld:pubmed
pubmed-article:16789729pubmed:authorsCompleteYlld:pubmed
pubmed-article:16789729pubmed:pagination3753-6lld:pubmed
pubmed-article:16789729pubmed:meshHeadingpubmed-meshheading:16789729...lld:pubmed
pubmed-article:16789729pubmed:meshHeadingpubmed-meshheading:16789729...lld:pubmed
pubmed-article:16789729pubmed:meshHeadingpubmed-meshheading:16789729...lld:pubmed
pubmed-article:16789729pubmed:meshHeadingpubmed-meshheading:16789729...lld:pubmed
pubmed-article:16789729pubmed:meshHeadingpubmed-meshheading:16789729...lld:pubmed
pubmed-article:16789729pubmed:meshHeadingpubmed-meshheading:16789729...lld:pubmed
pubmed-article:16789729pubmed:meshHeadingpubmed-meshheading:16789729...lld:pubmed
pubmed-article:16789729pubmed:meshHeadingpubmed-meshheading:16789729...lld:pubmed
pubmed-article:16789729pubmed:meshHeadingpubmed-meshheading:16789729...lld:pubmed
pubmed-article:16789729pubmed:meshHeadingpubmed-meshheading:16789729...lld:pubmed
pubmed-article:16789729pubmed:meshHeadingpubmed-meshheading:16789729...lld:pubmed
pubmed-article:16789729pubmed:meshHeadingpubmed-meshheading:16789729...lld:pubmed
pubmed-article:16789729pubmed:meshHeadingpubmed-meshheading:16789729...lld:pubmed
pubmed-article:16789729pubmed:meshHeadingpubmed-meshheading:16789729...lld:pubmed
pubmed-article:16789729pubmed:meshHeadingpubmed-meshheading:16789729...lld:pubmed
pubmed-article:16789729pubmed:meshHeadingpubmed-meshheading:16789729...lld:pubmed
pubmed-article:16789729pubmed:meshHeadingpubmed-meshheading:16789729...lld:pubmed
pubmed-article:16789729pubmed:year2006lld:pubmed
pubmed-article:16789729pubmed:articleTitleA thienopyridazinone-based melanin-concentrating hormone receptor 1 antagonist with potent in vivo anorectic properties.lld:pubmed
pubmed-article:16789729pubmed:affiliationNeurocrine Biosciences Inc., 12790 El Camino Real, San Diego, California 92130, USA. bdyck@neurocrine.comlld:pubmed
pubmed-article:16789729pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...http://linkedlifedata.com/r...pubmed-article:16789729lld:chembl